1 The subtypes of a 1 -adrenoceptor mediating contractions of rat vas deferens to endogenous and exogenous noradrenaline and to the exogenous agonists methoxamine, phenylephrine and A61603 have been examined. 2 The eects of antagonists on the shape of concentration-response curves, both tonic and phasic, to the four agonists were analysed. Prazosin produced parallel shifts in all cases. Particularly for RS 17053 against noradrenaline, there was some evidence for a resistant component of the agonist response. High concentrations of RS 17053 (1 ± 10 mM) virtually abolished tonic contractions but phasic contractions were resistant. 3 A series of nine antagonists (the above and WB4101, benoxathian, phentolamine, BMY 7378, HV 723, spiperone) were investigated against contractions to noradrenaline. The correlation with the potency of the series of a 1 -adrenoceptor antagonists against contractions to noradrenaline was signi®cant only for the a 1A -adrenoceptor ligand binding site (r=0.88, n=9, P50.01). 4 In epididymal portions (nifedipine 10 mM), the isometric contraction to a single electrical pulse is a 1 -adrenoceptor mediated. The correlation with ligand binding sites for 11 antagonists (the above plus ARC 239 and (+)-niguldipine) was signi®cant only for the a 1D -adrenoceptor subtype (r=0.65, n=11, P50.05). 5 In conclusion, tonic contractions of rat vas deferens produced by exogenous agonists are mediated predominantly by a 1A -adrenoceptors, although a second subtype of receptor may additionally be involved in phasic contractions. Nerve-stimulation evoked a 1 -adrenoceptor mediated contractions seem to predominantly involve non-a 1A -adrenoceptors, and the receptor involved resembles the a 1D -receptor.
Introduction a 1 -Adrenoceptors were initially subdivided into a 1A -and a 1B -subtypes in ligand binding studies, based on the anities of a series of ligands, especially WB 4101 and prazosin (Morrow & Creese, 1986) , and based on the ability of the alkylating agent chloroethylclonidine (CEC) to inactive the a 1B -but not the a 1A -subtype (Han et al., 1987) . Molecular cloning techniques revealed initially four subtypes of a 1 -adrenoceptor: a 1a , a 1b , a 1c , a 1d (Cotecchia et al., 1988; Schwinn et al., 1990; Lomasney et al., 1991; Perez et al., 1991; see Bylund et al., 1994) . However, the a 1a and a 1d clones showed 99.8% homogeneity and appeared to represent the same subtype. It is now clear that the a 1a /a 1d clone represents a novel subtype of a 1 -adrenoceptor (a 1D ), whereas the a 1c is now identi®ed with the a 1A -ligand binding site. These clones have now been renamed to match the functional receptors: a 1A (formely a 1c ), a 1B (formerly a 1b ), and a 1D (formerly a 1a /a 1d ).
One of the earliest functional subclassi®cations of a 1 -adrenoceptors was into a 1H and a 1L , with high and low anity for prazosin (see Flavahan & Vanhoutte, 1986 but see Docherty, 1987; Muramatsu et al., 1990) . a 1 -Adrenoceptors in blood vessels were further subdivided into three subtypes, a 1H , a 1N and a 1L , based on their anities for prazosin, WB 4101 and HV 723 (Muramatsu et al., 1990) . Under this classi®ca-tion, a 1H -receptors have high anity for prazosin, and appear to match the a 1A , a 1B , a 1D classes (Muramatsu et al., 1995) , whereas a 1L and a 1N have low anity for prazosin and do not seem to match current molecular cloning based classi®cations.
New a 1 -adrenoceptor antagonists have been developed for eects in the lower urinary tract to treat benign prostatic hypertrophy, and the receptors involved were identi®ed as a 1A -adrenoceptors. However, some antagonists which were selective for a 1A -adrenoceptors in ligand binding studies had low potencies in functional studies of the lower urinary tract (RS 17053: Ford et al., 1996; Kenny et al., 1996; SB 216469: Chess-Williams et al., 1996) .
It has been variously suggested that contractions of rat vas deferens to exogenous noradrenaline or adrenaline are mediated predominantly by a 1A -adrenoceptors (Han et al., 1987; Hanft & Gross, 1989; Aboud et al., 1993) , or a 1L -in addition to a 1A -adrenoceptors (Ohmura et al., 1992) . The objects of this study were to re-examine the a 1 -adrenoceptor subtypes present in rat vas deferens in the light of current knowledge of a 1 -adrenoceptor subtypes and using some of the newer subtype selective compounds. Some of these results have been published in shortened form (Docherty, 1998) .
Rat vas deferens
Whole vas deferens, or prostatic or epididymal portions were obtained. Tissues were attached to myograph transducers under 1 g tension in organ baths at 378C in Krebs ± Henseleit solution of the following composition: (mM): NaCl 119; NaHCO 3 25; D-glucose 11.1; KCl 4.7; CaCl 2 2.5; KH 2 PO 4 1.2; MgSO 4 1.0; EDTA 0.03, ascorbic acid 0.28. Additionally, cocaine (3 mM), propranolol (3 mM) and indomethacin (10 mM) were present except where otherwise stated.
In investigations of contractions produced by exogenous agonists, tissues were equilibrated for 30 min and then contracted with noradrenaline (10 mM). Bathing¯uid was then changed every 15 min for the next hour. Following 60 min exposure to antagonist or vehicle, a single agonist concentration response-curve was obtained per tissue. Tissues were contracted with noradrenaline, methoxamine, phenylephrine or A61603 administered cumulative in 0.5 log unit increments beginning with 1 nM. Antagonist potency was expressed as the dissociation constant K B from the equation K B =[B]/(DR-1), where [B] is the concentration of antagonist and DR is the agonist dose-ratio produced by the antagonist as compared to the vehicle experiment, or as a pA 2 Value. Antagonist pA 2 values were obtained from the x-intercept of the plot of log (agonist DR-1) against log antagonist concentration, where the slope was not signi®cantly dierent from negative unity (Arunlakshana & Schild, 1959) . Slopes of Schild plots not signi®cantly dierent from 71.0 were constrained to 71.0, and a pK B was obtained. In cases when slopes of Schild plots were signi®cantly dierent from negative unity, or when a single concentration of antagonist was employed, antagonist potency was expressed as a pK B from the eects of a single eective concentration of antagonist.
In experiments investigating the ability of competitive antagonists to inhibit the isometric twitch in epididymal portions of vas deferens (in the presence or absence of cocaine), tissues were placed between platinum electrodes and stimulated every 5 min with a single stimulus (0.5 ms pulses, supramaximal pulses) to produce isometric contractions, and nifedipine (10 mM) was present to block the non-noradrenergic component of the twitch. Antagonists or vehicle were added cumulative in 1 log unit increments at 5 min intervals. An isometric twitch was obtained following 5 min exposure to each antagonist concentration, or following exposure to the vehicle. 
Results

Whole vas deferens: responses to exogenous agonists
In whole vas deferens, agonists produced contractions consisting of intermittent spikes superimposed on a tonic contraction: phasic contractions were measured as the total increase above baseline and so includes the spike and tonic components (see Figure 1) . The agonists noradrenaline, methoxamine, phenylephrine and A61603 produced tonic contractions with pD 2 values of 5.84+0.12, 5.53+0.07, 5.52+0.06 and 7.98+0.16 g and maximum contractions of 1.34+0.09, 1.05+0.08, 1.40+0.07 and 1.33+0.09 g, respectively (n=21 in all cases). The maximum tonic contraction to methoxamine was signi®cantly less than the maximum to the other agonists (Analysis of Variance, P50.05). The agonists noradrenaline, methoxamine, phenylephrine and A61603 produced phasic contractions with pD 2 values of 5.59+0.11, 5.28+0.10, 5.25+0.08 and 7.74+0.15 g and maximum contractions (measured as the maximum height of tonic contractions combined with intermittent spikes) of 2.11+0.11, 2.04+0.10, 2.26+0.15 and 2.16+0.11 g, respectively (n=21 in all cases).
The eects of prazosin (10 ± 30 nM), RS 17053 (100 nM) and 5-methyl-urapidil (30 nM) on tonic contractions to noradrena- line and phasic contractions to the four agonists are shown in Figures 2 ± 3. Phasic contractions are omitted for the other three antagonists, since tonic and phasic contractions were aected similarly by antagonists. Prazosin produced parallel shifts in all cases, and all antagonists produced parallel shifts in the potency of A61603. RS 17053 and 5-methyl-urapidil tended to produce apparently non-parallel shifts in the potency of noradrenaline and methoxamine, and to a lesser extent phenylephrine, but the resistant component was small ( Figures  2 ± 3 ).
However, a component particularly of the phasic contractions were resistant to high concentrations of antagonists; this was particularly evident for RS 17053 against noradrenaline. The eects of high concentrations of RS 17053 were investigated against tonic and phasic contractions to noradrenaline in terms of absolute tension developed (Figure 4 ). RS 17053 (1 mM) signi®cantly reduced the maximum tonic contraction to 0.57+0.10 g (n=4), without aecting maximum phasic contractions. RS 17053 (10 mM) signi®cantly reduced tonic contractions to 0.18+0.05 g (n=9) and signi®cantly reduced phasic contractions to 1.14+0.22 g (n=9). In the ®gure, noradrenaline pD 2 for phasic contractions in vehicle experiments was 5.59+0.21, and the pD 2 was shifted approximately 10 fold by RS 17053 (0.1 mM) (pD 2 ) of 4.50+0.14) and by RS 17053 (1 mM) (pD 2 component of the response resistant even to RS 17053 (10 mM) (Figure 4) .
Prazosin produced concentration-dependent shifts in the potency of all four agonists, and behaved competitively in that it did not decrease the maximum contraction, and slope of the Schild plot were not signi®cantly dierent from negative unity, so that pA 2 values could be calculated (Table 1) . However, in terms of slope of Schild plots, 5-methylurapidil behaved noncompetitively against phenylephrine and RS17053 behaved competitively against methoxamine (see Table 1 ). However, pK B values from the eects of the lowest eective concentration were calculated whenever pA 2 values could not be calculated (Table 1) .
In addition to prazosin, 5-methyl-urapidil and RS 17053, WB4101, benoxathian, phentolamine, BMY 7378, HV 723 and spiperone were investigated against contractions to noradrenaline. pA 2 values were converted to pK B values by constraining the slope of Schild plots to 71. The pK B values obtained are shown in Table 2 . For some of the antagonists, pK B was calculated from the eects of a single concentration of antagonist producing an approximate 1 log unit (10 fold) shift in agonist potency: (mM): RS 17053 0.1, 1.16+0.06 g; phentolamine 1, 1.28+0.25 g; BMY 7378 1, 0.48+0.14 g; BMY 10, 1.42+0.30 g; HV 723 0.1, 1.24+0.10 g; spiperone 1, 1.16+0.18 g. These potencies were correlated with anities for a 1A , a 1B and a 1D -adrenoceptor ligand binding sites obtained by taking the mean of published values (see Tables 2, 3 and Figure 5 ). The correlation with the potency of the series of a 1 -adrenoceptor antagonists against contractions to noradrenaline was signi®cant for the a 1A -adrenoceptor ligand binding site (r=0.88, n=9, P50.01) (Figure 5 ). One of the published studies examined seven of the antagonists used in this study (all except benoxathian and spiperone; Ford et al., 1996) . Correlation at antagonist potency with the ligand binding data of Ford et al. (1996) was again signi®cant only for the a 1A -adrenoceptor (a 1A r=90, P50.01; a 1B r=0.66, n.s.; a 1D r=0.62, n=9, n.s.).
Epididymal portions of rat vas deferens: nerve-mediated responses
In epididymal portions of rat vas deferens, the initial biphasic twitch to a single electrical stimulus was reduced to a monophasic response by nifedipine (10 mM), which eliminates the ®rst (non-noradrenergic) phase, leaving the second (noradrenergic) phase. Under these conditions, the twitch to a single stimulus was 0.80+0.05 g (n=68), and antagonists reduced the size of the twitch in a concentration-dependent manner ( Figure 6 ). Antagonist potency was slightly reduced in the presence of cocaine, but the correlation between antagonist potency with and without cocaine was very close (r=0.98) so that cocaine did not change relative potencies (Figure 7) . A total of 11 antagonists were examined (those listed above plus ARC239 and (+)-niguldipine) and potencies (without cocaine) are shown in Table 2 . These potencies were correlated with anities for a 1A , a 1B and a 1D -adrenoceptor ligand binding sites obtained by taking the mean of published values (see Tables 2,  3 and Figure 8 ). The correlation with ligand binding sites was signi®cant only for the a 1D -adrenoceptor subtype (r=0.65, a b Figure 4 Tonic (a) and phasic (b) contractions obtained to noradrenaline in whole vas deferens expressed as absolute tension (g), following exposure to vehicle (veh), RS 17053 (100 nM) (RS-7), RS 17053 (1 mM) (RS-6), DMSO or RS 17053 (10 mM) (RS-5). Vertical bars represent s.e.mean from at least four experiments. For clarity, vehicle experiments for the two lower concentrations of RS 17053 are combined but, since DMSO, the vehicle for the highest concentration of RS 17053 (10 mM), also produced signi®cant eects, this is included separately. n=11, P50.05) (Figure 8 ). One of the published studies examined eight of the antagonists used in this study (all except ARC 239, benoxathian and spiperone; Ford et al., 1996) . Correlation of antagonist potency with the ligand binding data of Ford et al. (1996) was not signi®cant for any a 1 -adrenoceptor subtype (a 1A r=0.01, n.s.; a 1B r=0.16, n.s.; a 1D r=0.53, n.s.).
Discussion
In this study, we have looked at subtypes of a 1 -adrenoceptor mediating contractions of the rat vas deferens to exogenous agonists (noradrenaline, methoxamine phenylephrine or A61603) and contractions to endogenous noradrenaline. These will be discussed separately, beginning with contractions to exogenous agonists.
Responses to exogenous agonists
In whole vas deferens, the agonists noradrenaline, methoxamine, phenylephrine and A61603 produced concentrationdependent contractions which consisted of intermittent spikes superimposed on a smaller tonic contraction: all agonists behaved apparently similarly in terms of producing tonic and phasic contractions. Phasic contractions were measured as the total contraction, i.e. the tonic contraction plus the intermittant spike. Agonists tended to be slightly more potent at producing tonic than phasic contractions, but this was simply because the tonic contraction dominated at low agonist concentrations (see Figure 1 ) and the maximum phasic contraction was signi®cantly greater than the maximum tonic contraction. The potencies of noradrenaline, phenylephrine and A61603 obtained in this study are similar to potencies obtained to these agonists in rat vas deferens by Knepper et al. (1995) . In the absence of antagonists, both tonic and phasic contractions to all agonists showed monophasic concentration-response curves. The antagonist prazosin produced approximately parallel shifts in the potency of all four agonists, and RS 17053 and 5-methyl-urapidil produced parallel shifts in the potency of A61603. However, for the agonists noradrenaline and methoxamine (and to a lesser extent phenylephrine), both RS 17053 and 5-methyl-urapidil tended to produce non-parallel shifts such that the potency of the agonist was shifted more at higher than lower concentrations. However, these dierences were relatively small and dicult to quantify.
We chose to compare antagonist potencies against noradrenaline with published ligand binding data for the three a 1 -adrenoceptor sites; we followed the method of Marshall et al. (1996) in taking the mean of several published ligand binding anities for each antagonist at each site (see Table 3 ). We chose nine antagonists; RS 17053, BMY 7378, phentolamine, HV723 and spiperone in addition to the above: BMY 7378 is especially interesting as an a 1D -selective antagonist (Goetz et al., 1995) which has higher potency as an antagonist in rat aorta, but lower potency in vas deferens (Deng et al., 1996) . Given the evidence for two components to the contractile response, it is perhaps not surprising that some Schild plots to RS 17053 and 5-methyl-urapidil demonstrated non-competitive interactions. The correlation between published data for ligand binding sites and the antagonist potencies obtained in our results would con®rm the identi®ca-tion of the predominant receptor mediating contractions of rat vas deferens to noradrenaline as an a 1A -adrenoceptor. This agrees with other studies of agonist contractions in rat vas deferens (Teng et al., 1994; Burt et al., 1995) . However, it is clear from the above that a second receptor is involved in contractions to noradrenaline, but it appears that none of the antagonists employed is selective for that receptor, although 5- methyl-urapidil and RS 17053 showed low potency at this second site. A component of the response to noradrenaline in rat vas deferens resistant to 5-methyl-urapidil has previously been reported in studies in which the antagonist was given subsequent to the agonist (Bultmann et al., 1994) .
High concentration of RS 17053 virtually abolished tonic contractions to noradrenaline, presumably by competitive antagonism, but were less eective against phasic contractions. However, the problem in comparing phasic concentrations with and without high concentrations of antagonist is the phasic contractions have a large tonic component in the absence of antagonist which may obscure the spikes. Both tonic and phasic contractions were abolished by pretreatment with phenoxybenzamine (10 mM), and the alkylating agent CEC (100 mM) did not signi®cantly aect tonic or phasic contractions to noradrenaline, but directly produced phasic contractions (spikes) (Aboud et al., 1993, and unpublished) . In the presence of the calcium entry blocker nifedipine, the intermittent spikes produced by noradrenaline were abolished, and a small tonic contraction remained (Aboud et al., 1993) . Since the phasic contraction to noradrenaline could not be Figure 5 Correlation between published antagonist anity for a 1A -, a 1B -and a 1D -ligand binding sites (data from Perez et al., 1991; Schwinn & Lomasney, 1992; Faure et al., 1994; Forray et al., 1994; Goetz et al., 1995; Knepper et al., 1995; Marshall et al., 1996; Ford et al., 1996; Kenny et al., 1996) and antagonist postjunctional potency (pK B ) against contractions to noradrenaline in whole vas deferens. Numbers indicate compounds as listed in Tables 2 and 3 . Vertical and horizontal bars indicate s.e.mean. There was a signi®cant correlation between antagonist postjunctional potency and anity for a 1A -adrenoceptor ligand binding site. examined in isolation, the a 1 -adrenoceptor mediated response to nerve stimulation was examined in more detail.
Responses to endogenous noradrenaline
In rat whole vas deferens, the electrical stimulation-evoked contraction to a single stimulus consists of a biphasic response, the ®rst phase of which is non-adrenoceptor mediated and predominates in prostatic portions, and the second phase of which is a 1 -adrenoceptor mediated, and predominates in the epididymal portion (Brown et al., 1983) . The second anoradrenergic phase can be examined in isolation in the epididymal portion in the presence of nifedipine which eliminates the second non-noradrenergic response. Antagonist potencies at inhibiting this stimulation-evoked a 1 -adrenoceptor mediated contraction were obtained both in the absence and presence of cocaine. Cocaine blocks the uptake of noradrenaline back into the nerve terminal, and so prolongs and potentiates contractions: antagonists tended to be less potent at inhibiting contractions in the presence of cocaine, but antagonist potencies with or without cocaine correlated well with each other. Antagonist potencies at inhibiting nerveevoked contractions in epididymal portions did not correlate with a 1A -adrenoceptors, but signi®cantly correlated only with the a 1D -adrenoceptor ligand binding site, even though the correlation was relatively low (r=0.65), due largely to one outlier, 5-methyl-urapidil. Interestingly, when 5-methyl-urapidil is eliminated from the correlation, there was a much improved correlation with a 1D -adrenoceptors (r=0.90, P50.001). In the present study, the relatively high potency of BMY 7378 against nerve stimulation-evoked contractions (pIC 50 of 7.45) may also suggest an a 1D -adrenoceptor. Since the a 1D -receptor is reported to be expressed in rat vas deferens (Perez et al., 1991; Rokosh et al., 1994) , the above receptor may represent a function a 1D -adrenoceptor. Bultmann et al. (1994) investigated nerve mediated responses in rat vas deferens and found that 5-methyl-urapidil was approximately ten times less potent than WB 4101, a potency which would also aid identi®cation with a 1D -adrenoceptors. The high potency of 5-methyl-urapidil in our study is dicult to explain, but may suggest other actions of this compound. Because of this, we re-examined the potency of 5-methyl-urapidil: in our experiments the pIC 50 varied between 10.0 and 8.00, with a mean of 8.97. This range of values is much greater than for other antagonists (e.g. benoxathian: 7.22 ± 7.70). Although 5-methyl-urapidil is reported to bind with high anity to 5-HT-1A receptors (Zilles et al., 1991) , its inhibitory action in rat vas deferens is not antagonized by the 5-HT-1 receptor antagonist cyanopindolol (authors, unpublished) . An a 1D -adrenoceptor should show some sensitivity to block by CEC, and the nerveevoked adrenergic contraction of rat vas deferens is indeed blocked by CEC (Mallard et al., 1992; Aboud et al., 1993) , but this action of CEC is at least partly prejunctional (Bultmann & Starke, 1993 ). An a 1D -adrenoceptor has also been reported to mediated nerve-evoked pressor responses in the pithed rat preparation (Castillo et al., 1998) .
Finally, how do we explain the contradictory ®ndings in the literature concerning the a 1 -adrenoceptor subtype mediating contractions of rat vas deferens? Clearly with two subtypes present, dierent experimental conditions may favour the dominance of one or other of the subtypes so that both a 1A -and a 1L -adrenoceptors have been reported. Genetic polymorphism of a 1A -adrenoceptors does not explain a 1L -adrenoceptors, since all variants have been found to have similar pharmacological characteristics (Shibata et al., 1996) . The a 1A -adrenoceptor, expressed in the CHO-K1 cell line, displayed Figure 8 Correlation between published antagonist anity for a 1A -, a 1B -and a 1D -ligand binding sites (data from Perez et al., 1991; Schwinn & Lomasney, 1992; Faure et al., 1994; Forray et al., 1994; Goetz et al., 1995; Knepper et al., 1995; Marshall et al., 1996; Ford et al., 1996; Kenny et al., 1996) and antagonist postjunctional potency (pIC 50 ) against stimulation-evoked contractions to a single stimulus in epididymal portions of rat vas deferens in the presence of nifedipine (10 mM). Numbers indicate compounds as listed in Tables 2  and 3 . Vertical and horizontal bars indicate s.e.mean. There was a signi®cant correlation between antagonist potency and anity for the a 1D -adrenoceptor ligand binding site.
binding properties of the a 1A -adrenoceptor but functionally, in terms of inositol phosphate accumulation, the receptor displayed properties of the a 1L -adrenoceptor (Ford et al., 1996) . Hence, presumably due to factors determined by the methodology employed, and perhaps due to environmental dierences around the receptor, the same receptor can show characteristics of both a 1A -and a 1L -adrenoceptors: hence a 1A -and a 1L may be dierent anity/conformational states of the a 1A -adrenoceptor. The additional presence of an a 1D -adrenoceptor complicates matters further.
In conclusion, we have studied contractile responses of rat vas deferens to exogenous agonists and to electrical stimulation. Tonic and phasic contractions of rat vas deferens produced by exogenous agonists are mediated predominantly by a 1A -adrenoceptors, although particularly phasic contractions may have a second component. Nerve-evoked contractions seem to be mediated predominated by non-a 1A -adrenoceptors, and the receptor involved resembles the a 1D -receptor.
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